What is Vivid Genomics?
Vivid Genomics is at the forefront of enhancing drug development for dementia, leveraging precision medicine to tackle critical challenges in neurodegenerative disease. The company employs advanced machine learning and genomics to develop proprietary blood-based genetic tests, branded as Genomic Biopsy. These tests, including AmyloidGB for amyloid plaque detection and ProgressionGB for predicting disease progression, are designed to significantly improve patient stratification and clinical trial outcomes for conditions like Alzheimer's disease. Pharmaceutical companies are increasingly turning to such precise diagnostic tools to optimize clinical trial success rates and refine patient selection processes.
How much funding has Vivid Genomics raised?
Vivid Genomics has raised a total of $38K across 1 funding round:
Debt
$38K
Debt (2021): $38K with participation from PPP
What's next for Vivid Genomics?
With the recent substantial expansion capital, Vivid Genomics is poised for significant scaling and further development of its Genomic Biopsy technology. This funding is expected to accelerate the company's efforts in clinical validation, market penetration, and potentially the expansion of its diagnostic capabilities to other neurodegenerative conditions. The strategic investment at this Series B/C stage suggests a focus on commercialization and solidifying its market position as a leader in precision diagnostics for neurological disorders.
See full Vivid Genomics company page
